CAJ | 학술논문

原发中枢神经系统淋巴瘤目前尚无最佳治疗方案，以高剂量甲氨蝶呤（HD-MTX）为基础的化疗是目前推荐的一线治疗方案。利妥昔单抗治疗原发中枢神经系统淋巴瘤已初见疗效，但尚需临床试验确定。HD-MTX加巩固放疗能提高缓解率，但是由于其延迟神经毒性，并不能延长总生存期，是否需要巩固放疗仍存在争议。大剂量化疗+自体干细胞移植（HDC+ASCT）是原发中枢神经系统淋巴瘤有效的巩固及挽救治疗方法，其最佳治疗方案仍需进一步探索。
원발중추신경계통림파류목전상무최가치료방안，이고제량갑안접령（HD-MTX）위기출적화료시목전추천적일선치료방안。리타석단항치료원발중추신경계통림파류이초견료효，단상수림상시험학정。HD-MTX가공고방료능제고완해솔，단시유우기연지신경독성，병불능연장총생존기，시부수요공고방료잉존재쟁의。대제양화료+자체간세포이식（HDC+ASCT）시원발중추신경계통림파류유효적공고급만구치료방법，기최가치료방안잉수진일보탐색。
Currently, since there is no optimal standard treatment regimen for primary central nervous system lymphoma (PCNSL), the high-dose methotrexate (HD-MTX) based chemotherapy is the recommended first-line therapy. Rituximab in PCNSL treatment has shown signs of efficacy but still requires adequate clinical randomized trials to prove. HD-MTX plus consolidation radiotherapy can improve the response rate, but the treatment regimen can not prolong overall survival due to delayed neurotoxicity, so it is controversial yet to adopt consolidate radiotherapy. High-dose chemotherapy with autologous stem cell transplantation (HDC+ASCT) is the effective consolidation and salvage therapy for PCNSL, but its optimal regi-men needs further exploration.